Publications:78
Video Visit Available
Accepting New Patients
Mount Sinai DoctorsTreats Adults
Accepting New PatientsHearn Jay Cho, MD, PhD
Hematology-Oncology, Cancer (Oncology)
No Patient Experience Ratings
Book an Appointment
About Me
Hearn Jay Cho, MD, PhD, is Associate Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.
Dr. Cho specializes in clinical care and research in multiple myeloma and related diseases. Dr. Cho received his medical degree and doctorate in Immunology at the Weill Medical College of Cornell University and did residency training in Internal Medicine at the University of California, San Diego. He was a clinical fellow in Hematology and Medical Oncology at Weill Medical College. In addition to his clinical training, Dr. Cho did post-doctoral training in Immunology at the University of California San Diego and Rockefeller University in New York. He has more than 20 years of experience as an investigator on clinical trials and actively manages patients on clinical trials for multiple myeloma and amyloidosis at Mount Sinai. Many of the trials involve collaborative translational research with cancer immunology groups at Mount Sinai and other institutions.
Dr. Cho’s research focuses on novel targeted therapies for multiple myeloma. His laboratory is developing combination strategies based on therapeutic tumor vaccines to elicit protective host immune responses against tumor cells, and is investigating the biochemical and molecular pathways of Melanoma Antigen Gene (MAGE) activity—MAGE is a family of cancer-associated genes the confer resistance to apoptosis in proliferating multiple myeloma cells.
Active in education, Dr. Cho mentors many graduate students, fellows in Hematology and Medical Oncology, fellows in Bone Marrow Transplantation, and postdoctoral research fellows.
Dr. Cho is a member of the Immunology Institute at Mount Sinai. He serves as a Multiple Myeloma Expert Reviewer for the Cancer Research Institute and is on the Board of Directors for Solving Kids Cancer. In addition to his academic duties at Mt. Sinai, Dr. Cho is the Chief Medical Officer of the Multiple Myeloma Research Foundation, where he oversees the clinical research program.
The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.
Language
Position
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
Multi-Disciplinary Training Areas
Disease Mechanisms and Therapeutics (DMT)
About Me
Hearn Jay Cho, MD, PhD, is Associate Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.
Dr. Cho specializes in clinical care and research in multiple myeloma and related diseases. Dr. Cho received his medical degree and doctorate in Immunology at the Weill Medical College of Cornell University and did residency training in Internal Medicine at the University of California, San Diego. He was a clinical fellow in Hematology and Medical Oncology at Weill Medical College. In addition to his clinical training, Dr. Cho did post-doctoral training in Immunology at the University of California San Diego and Rockefeller University in New York. He has more than 20 years of experience as an investigator on clinical trials and actively manages patients on clinical trials for multiple myeloma and amyloidosis at Mount Sinai. Many of the trials involve collaborative translational research with cancer immunology groups at Mount Sinai and other institutions.
Dr. Cho’s research focuses on novel targeted therapies for multiple myeloma. His laboratory is developing combination strategies based on therapeutic tumor vaccines to elicit protective host immune responses against tumor cells, and is investigating the biochemical and molecular pathways of Melanoma Antigen Gene (MAGE) activity—MAGE is a family of cancer-associated genes the confer resistance to apoptosis in proliferating multiple myeloma cells.
Active in education, Dr. Cho mentors many graduate students, fellows in Hematology and Medical Oncology, fellows in Bone Marrow Transplantation, and postdoctoral research fellows.
Dr. Cho is a member of the Immunology Institute at Mount Sinai. He serves as a Multiple Myeloma Expert Reviewer for the Cancer Research Institute and is on the Board of Directors for Solving Kids Cancer. In addition to his academic duties at Mt. Sinai, Dr. Cho is the Chief Medical Officer of the Multiple Myeloma Research Foundation, where he oversees the clinical research program.
The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.
Language
Position
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
Multi-Disciplinary Training Areas
Disease Mechanisms and Therapeutics (DMT)
Clinical Focus
- Multiple Myeloma
- Smoldering Myeloma
Education
MD, Weill Medical College of Cornell University
Residency, Internal Medicine
University of California Medical Center San Diego
Fellowship, Hematology & Oncology
New York Presbyterian Hospital-Weill Cornell
Certifications
American Board of Internal Medicine
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.
- Ruttenberg Treatment Center1470 Madison Avenue, 3rd Floor, New York, NY, 10029
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Correction to: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes (Nature Genetics, (2024), 56, 9, (1878-1889), 10.1038/s41588-024-01853-0). Sheri Skerget, Daniel Penaherrera, Ajai Chari, Sundar Jagannath, David S. Siegel, Ravi Vij, Gregory Orloff, Andrzej Jakubowiak, Ruben Niesvizky, Darla Liles, Jesus Berdeja, Moshe Levy, Jeffrey Wolf, Saad Z. Usmani, Ronald Steis, Shanti Srinivas, Vivek Roy, Paula Rodríguez, Albert Oriol, Shaji Kumar, Isabel Krsnik, May Matkiwsky, Saulias Girnius, Miguel Conde, Sumeet Chandra, Robert Anderson, William Solomon, Donald Richards, Dilip Patel, Alex Menter, Hakan Kaya, Gerald Hsu, Hani Hassoun, Joan Bargay, Larry Anderson, Eugenia Abella, Madhuri Yalamachili, William Wachsman, Fabio Volterra, Adedayo Onitilo, Fredrick Min, Marie Shieh, Michael Bar, Justinian Ngaiza, Wayne Harris, Michael Sebag, Robert Robles, Kathleen Yost, Michael Grossbard, Hearn Jay Cho. Nature Genetics
- Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma. Darren Pan, Tarek H. Mouhieddine, Tianxiang Sheng, Weijia Fu, Erin Moshier, Joshua Richter, Samir Parekh, Sundar Jagannath, Adriana C. Rossi, Larysa J. Sanchez, Santiago Thibaud, Cesar Rodriguez, Hearn J. Cho, Shambavi Richard. Bone Marrow Transplantation
- Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial. Shambavi Richard, Alexander M. Lesokhin, Barry Paul, Jonathan L. Kaufman, Matthew Pianko, Noa Biran, Ravi Vij, Deon B. Doxie, Maryam I. Azeem, Mercedes Martillo, Katie Wozniak, Hearn J. Cho, Kavita M. Dhodapkar, Madhav V. Dhodapkar. Nature Cancer
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Cho during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Guidepoint
- GRAIL, Inc
Outside Employment
- Multiple Myeloma Research Foundation (MMRF)
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Cho during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Guidepoint
- GRAIL, Inc
Outside Employment
- Multiple Myeloma Research Foundation (MMRF)
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.